1. Home
  2. NOTV vs RFL Comparison

NOTV vs RFL Comparison

Compare NOTV & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inotiv Inc.

NOTV

Inotiv Inc.

N/A

Current Price

$0.40

Market Cap

12.7M

Sector

Health Care

ML Signal

N/A

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

N/A

Current Price

$1.48

Market Cap

61.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
NOTV
RFL
Founded
1974
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
12.7M
61.1M
IPO Year
1997
2017

Fundamental Metrics

Financial Performance
Metric
NOTV
RFL
Price
$0.40
$1.48
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$1.50
N/A
AVG Volume (30 Days)
575.0K
91.0K
Earning Date
05-14-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
49.64
28.28
EPS
N/A
N/A
Revenue
$547,656,000.00
$917,000.00
Revenue This Year
$5.28
N/A
Revenue Next Year
$5.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
511.19
43.96
52 Week Low
$0.25
$1.12
52 Week High
$3.35
$3.19

Technical Indicators

Market Signals
Indicator
NOTV
RFL
Relative Strength Index (RSI) 53.23 65.63
Support Level $0.26 $1.41
Resistance Level $0.65 $1.63
Average True Range (ATR) 0.05 0.10
MACD 0.03 0.02
Stochastic Oscillator 70.04 71.25

Price Performance

Historical Comparison
NOTV
RFL

About NOTV Inotiv Inc.

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Share on Social Networks: